DR. VIDHI ANKLESARIA

DR. SOUMYA H.V., DR. PRABHAKAR S.K., DR. SHILPA G., DR. KEERTHI KUMAR

Abstract

Aim: To determine relationship of systemic risk factors and clinical findings with anti VEGF therapy outcome in eyes with macular edema along with RVO. Material and methods: Records of 51 patients of macular edema secondary to Branch RVO and Central RVO were analyzed and followed up for 6-months after Intravitreal Anti-VEGF in a retrospective descriptive study. Results: Among 37 BRVO and 14 CRVO cases, STBRVO was most frequent (33.33%). 28 males (54.9%) and 23 females (45.1%) were studied. Maximum incidence of RVO was between 60–69 years. Atherosclerotic diseases accounted for 76.47% as the commonest systemic abnormality. 23 patients (45.1%) needed repeat anti-VEGF, with no improvement of visual acuity in 9. Statistically significant decrement of CFT post injection with no difference in patients receiving single and multiple injections.

Conclusion: Treatment of underlying medical conditions is of potential value along with a frequent follow up in preventing recurrence of RVO.